tiprankstipranks
Procept Biorobotics Corp. (PRCT)
:PRCT
US Market

PROCEPT BioRobotics (PRCT) Earnings Dates, Call Summary & Reports

Compare
450 Followers

Earnings Data

Report Date
Apr 24, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
-0.49
Last Year’s EPS
-0.51
Same Quarter Last Year
Based on 11 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Feb 25, 2025
|
% Change Since: -1.51%
|
Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful product launches, and progress in prostate cancer treatment initiatives. However, it also acknowledged challenges such as a significant saline supply disruption affecting procedure volumes and higher-than-expected operating expenses.
Company Guidance
During the PROCEPT BioRobotics Fourth Quarter and Year End 2024 Earnings Conference Call, the company provided comprehensive guidance for 2025, highlighting expectations for total revenue to reach approximately $320 million, a growth of 43% compared to 2024. They anticipate selling around 210 new robotic systems, with average selling prices ranging from $430,000 to $440,000. The company expects to sell approximately 52,500 handpieces at an average selling price of $3,200. International revenue is projected to grow by 36% to $32.5 million, driven by momentum in the UK and Japan. Gross margins for 2025 are anticipated to be about 64.5%, reflecting a 400 basis point improvement over 2024. Operating expenses are expected to be approximately $300 million, up 28% from the previous year, with a significant portion attributed to noncash stock-based compensation. Overall, the company is focused on leveraging strong commercial execution, expanding its installed base, and advancing its prostate cancer initiatives to drive long-term growth.
Significant Revenue Growth
Total revenue for the fourth quarter of 2024 was $68.2 million, representing growth of 57% compared to the fourth quarter of 2023. The full year revenue was $224.5 million, marking a growth of 65%.
Successful HYDROS Robotic System Launch
Received FDA 510(k) clearance for the HYDROS Robotic System, which saw a positive market reception and exceeded expectations. HYDROS accounted for 95% of the 60 systems sold in Q4, with an average selling price of approximately $460,000.
Prostate Cancer Initiative Progress
Successfully demonstrated that Aquablation therapy does not spread cancer cells, leading to FDA lifting the contraindication for patients with prostate cancer. Initiated a pivotal randomized study for prostate cancer with FDA-IDE approval.
International Revenue Surge
International revenue in the fourth quarter was $7.8 million, representing growth of 137% compared to the prior year period, driven by strong sales in the UK.
Record Gross Margin
Achieved a record gross margin of 64% in Q4 2024, an improvement due to operational efficiencies and higher HYDROS System selling prices.
---

PROCEPT BioRobotics (PRCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PRCT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 24, 20252025 (Q1)
-0.49 / -
-0.51
Feb 25, 20252024 (Q4)
-0.34 / -0.35
-0.5435.19% (+0.19)
Oct 28, 20242024 (Q3)
-0.49 / -0.40
-0.5121.57% (+0.11)
Aug 01, 20242024 (Q2)
-0.52 / -0.50
-0.5610.71% (+0.06)
May 01, 20242024 (Q1)
-0.56 / -0.51
-0.6319.05% (+0.12)
Feb 27, 20242023 (Q4)
-0.44 / -0.54
-0.6314.29% (+0.09)
Nov 01, 20232023 (Q3)
-0.53 / -0.51
-0.510.00% (0.00)
Jul 27, 20232023 (Q2)
-0.57 / -0.56
-0.43-30.23% (-0.13)
Apr 27, 20232023 (Q1)
-0.58 / -0.63
-0.39-61.54% (-0.24)
Feb 28, 20232022 (Q4)
-0.54 / -0.63
-0.42-50.00% (-0.21)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

PRCT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 25, 2025$62.71$68.11+8.61%
Oct 28, 2024$68.77$91.00+32.33%
Aug 01, 2024$62.00$57.38-7.45%
May 01, 2024$52.98$60.61+14.40%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Procept Biorobotics Corp. (PRCT) report earnings?
Procept Biorobotics Corp. (PRCT) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
    What is Procept Biorobotics Corp. (PRCT) earnings time?
    Procept Biorobotics Corp. (PRCT) earnings time is at Apr 24, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PRCT EPS forecast?
          PRCT EPS forecast for the fiscal quarter 2025 (Q1) is -0.49.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis